IMNM Surges 12.7% on CEO Buy-In: Can Biotech Optimism Sustain the Momentum?

Summary
• Immunome CEO Clay Siegall acquires 25,450 shares at $19.67/share
• Intraday price soars to $22.22, up 12.7% from $20.37 open
• RSI at 27%, MACD bears still in control

Immunome’s shares are in a rare bullish spurt amid CEO buying and sector volatility. With the stock trading near its 52-week high of $27.65 and a sharp 12.7% intraday gain from its opening price, market participants are scrambling to assess the catalyst. The CEO’s direct purchase of $500k in shares and the broader biotech sector’s mixed performance have sparked questions about whether this is a short-lived rally or the start of a broader turnaround.

CEO Buy-In and Short-Term Optimism Fuel the Surge
Immunome's sharp intraday price increase of 12.7% is primarily attributed to the direct purchase of 25,450 shares by CEO Clay Siegall at a weighted average price of $19.67/share. Siegall's transaction, totaling $500,601, occurred ahead of the stock's current price surge, suggesting internal confidence in the company’s near-term direction. While the news does not include any new product updates or earnings catalysts, CEO buying often signals to the market that insiders believe the stock is undervalued. Given the biotech sector’s high volatility and Immunome’s ongoing clinical development in immunotherapy and DNA-based treatments, this insider activity is being interpreted as a bullish signal by momentum traders.

Biotech Sector Volatility Continues Amid Mixed Developments
The biotech sector remains in a period of mixed momentum. While Immunome surges on CEO buying, other sector leaders like Merck (MRK) are showing only modest gains (1.55%). Recent sector news includes a $25M Series A close for Amani Therapeutics, the expansion of insitro's collaboration with Bristol Myers Squibb, and MaaT Pharma presenting ARES Phase 3 data. These developments reflect a sector in transition, with early-stage companies attracting capital and late-stage players making strategic partnerships. Immunome’s move appears more aligned with insider confidence rather than broader sector momentum, but it highlights the continued volatility in biotech equities, particularly among clinical-stage firms.

Options & Technical Playbook: Ride the Momentum or Hedge the Volatility?
• 52W High: $27.65, 52W Low: $5.15
• 30D MA: 21.18, 200D MA: 16.02
• RSI: 26.98 (oversold), MACD: -0.67
• Bollinger Bands: Upper $22.26, Middle $20.76
• Implied Volatility (IV) across options: 30%–75%
• Theta and Gamma: Favor short-term traders

Immunome’s technicals show a bearish short-term trend with a long-term range-bound pattern. The RSI at 26.98 and MACD below zero suggest that the stock is oversold but still under downward pressure from trend lines. The Bollinger Bands have the stock at the upper limit, which may signal short-term exhaustion of the rally. With the 30D MA at $21.18 and the stock trading at $21.75, the move has just crossed into positive territory from its 30D average, potentially indicating a short-term reversal. Traders may consider using near-term options to capitalize on the volatility, especially if the stock holds above $20.75. Merck (MRK) is currently the sector leader with a modest intraday gain of 1.55%, but it’s not directly correlated to Immunome’s move, so leveraged ETFs may not be a core consideration in this case.

IMNM20260417C22
• Contract Code: IMNM20260417C22
• Type: Call
• Strike Price: $22
• Expiration Date: 2026-04-17
• IV: 60.19%
• Delta: 0.5215
• Theta: -0.057257
• Gamma: 0.135984
• Turnover: 7,233

IV is in the mid-to-high range (60.19%), suggesting market expectation of continued volatility. Delta of 0.5215 is ideal for short-term directional plays, and gamma of 0.135984 indicates strong sensitivity to price movement, which could be beneficial as the stock trades near the $22 strike. Theta is high (-0.057), suggesting time decay is noticeable, so this option is best for short-term traders expecting the stock to stay above $22.

IMNM20260417P23
• Contract Code: IMNM20260417P23
• Type: Put
• Strike Price: $23
• Expiration Date: 2026-04-17
• IV: 91.52%
• Delta: -0.5499
• Theta: -0.014088
• Gamma: 0.088871
• Turnover: 238

This put option is ideal for a more conservative short-side position. IV is very high (91.52%), indicating elevated volatility expectations. Delta of -0.55 is strong for short-side exposure, and gamma of 0.088871 offers reasonable sensitivity to price movement. Theta is low, which is preferable for holding this option over several days if the market remains uncertain.

Under a 5% upside projection (price to $22.84), the IMNM20260417C22 would yield a payoff of $0.84/share (i.e., $22.84 - $22). Given the high delta and moderate IV, this call could perform well if the stock continues to rise.

Aggressive bulls should consider IMNM20260417C22 into a retest above $22. If the move consolidates, IMNM20260417P23 offers a hedge against a potential reversal.

Backtest Immunome Stock Performance
The backtest of IMNM's performance following a 13% intraday increase from 2022 to the present reveals favorable short-to-medium-term gains. The 3-day win rate is 48.23%, the 10-day win rate is 50.00%, and the 30-day win rate is 56.89%, indicating a higher probability of positive returns in the immediate aftermath of the surge. The maximum return during the backtest was 17.17%, which occurred on day 59 after the event, suggesting that while there is some volatility, IMNM can continue to perform well in the weeks following the intraday surge.

A Short-Lived Rally or a Catalyst-Driven Breakout?
Immunome’s 12.7% intraday gain appears to be driven by a mix of CEO buying and short-term momentum, but the technicals remain bearish in the short term. Traders should keep a close eye on the $22.22 intraday high and whether the stock can close above the $20.75 mid-Bollinger Band. A sustained move above that could signal a breakout, but a retest of the $20.37 intraday low would likely reignite bearish sentiment. With Merck (MRK) showing only 1.55% gains as sector leader, Immunome’s move remains more of a speculative play than a sector-wide shift. Investors who want to stay on the sidelines can monitor the RSI and MACD to detect a potential trend reversal, while those with a stomach for risk might consider the short-term options outlined above.

Takeaway: Watch for a close above $22.22 for confirmation of momentum continuation, or a breakdown below $20.75 for a bearish signal. If you're looking for a sector play, Merck (MRK) is up 1.55%, but Immunome remains a high-volatility name with sharp upside potential. For now, it's a stock to watch — and a trade to evaluate with caution.